Suppr超能文献

非小细胞肺癌:小活检和细胞学标本的诊断难点:“临床医生病理学”系列第2号,由彼得·多夫米勒和阿尔贝托·卡瓦扎编辑。

Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series "Pathology for the clinician" Edited by Peter Dorfmüller and Alberto Cavazza.

作者信息

Bubendorf Lukas, Lantuejoul Sylvie, de Langen Adrianus J, Thunnissen Erik

机构信息

Institut für Pathologie, Universität Basel, Basel, Switzerland.

Dept of Biopathology, Centre Léon Bérard UNICANCER, Lyon, France.

出版信息

Eur Respir Rev. 2017 Jun 28;26(144). doi: 10.1183/16000617.0007-2017. Print 2017 Jun 30.

Abstract

The pathological and molecular classification of lung cancer has become substantially more complex over the past decade. For diagnostic purposes on small samples, additional stains are frequently required to distinguish between squamous cell carcinoma and adenocarcinoma. Subsequently, for advanced nonsquamous cell nonsmall cell lung carcinoma (NSCLC) patients, predictive analyses on epidermal growth factor receptor, anaplastic lymphoma kinase and ROS1 are required. In NSCLCs negative for these biomarkers, programmed death ligand-1 immunohistochemistry is performed. Small samples (biopsy and cytology) require "tissue" management, which is best achieved by the interaction of all physicians involved.

摘要

在过去十年中,肺癌的病理和分子分类变得复杂得多。出于对小样本的诊断目的,经常需要额外的染色来区分鳞状细胞癌和腺癌。随后,对于晚期非鳞状非小细胞肺癌(NSCLC)患者,需要对表皮生长因子受体、间变性淋巴瘤激酶和ROS1进行预测分析。对于这些生物标志物阴性的NSCLC患者,需进行程序性死亡配体-1免疫组织化学检测。小样本(活检和细胞学样本)需要“组织”管理,这最好通过所有相关医生的相互协作来实现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bddc/9488516/5ba33dbbb525/ERR-0007-2017.01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验